Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Prelude Therapeutics Ownership Summary

Prelude Therapeutics is owned by 5.33% institutional investors, 9.93% insiders, and 84.74% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.36% of PRLD shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.31% of its assets in Prelude Therapeutics shares.

PRLD Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Prelude Therapeutics	5.33%	9.93%	84.74%
Sector	Healthcare Stocks	232.51%	10.72%	-143.23%
Industry	Biotech Stocks	384.56%	10.58%	-295.14%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	10.91M	14.36%	$15.71M
Baker bros. advisors lp	10.12M	13.32%	$14.58M
Boxer capital	2.57M	3.39%	$9.79M
Vanguard group	1.41M	1.86%	$4.10M
Blackrock	1.07M	1.41%	$4.07M
Price t rowe associates inc /md/	876.34K	1.15%	$1.26M
Acadian asset management	535.70K	0.70%	$1.55M
Millennium management	462.56K	0.61%	$589.76K
Morgan stanley	334.92K	0.44%	$971.26K
Geode capital management	272.89K	0.36%	$791.50K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Boxer capital	2.57M	0.52%	$9.79M
Orbimed advisors	10.91M	0.37%	$15.71M
Baker bros. advisors lp	10.12M	0.11%	$14.58M
Shay capital	100.00K	0.01%	$144.00K
Caldwell sutter capital	2.00K	0.00%	$5.80K
Acadian asset management	535.70K	0.00%	$1.55M
Bridgeway capital management	53.50K	0.00%	$77.04K
Xtx topco	15.58K	0.00%	$22.43K
Renaissance	271.30K	0.00%	$786.77K
Two sigma advisers, lp	222.70K	0.00%	$320.69K

Top Buyers

Holder	Shares	% Assets	Change
Vanguard group	1.41M	0.00%	421.13K
Millennium management	462.56K	0.00%	302.03K
Jane street group	111.04K	-	76.22K
Susquehanna group, llp	72.80K	-	72.80K
Geode capital management	272.89K	-	55.32K

Top Sellers

Holder	Shares	% Assets	Change
Deerfield management company, l.p. (series c)	-	-	-3.77M
Exoduspoint capital management, lp	-	-	-921.62K
Avidity partners management lp	-	-	-890.00K
Massachusetts financial services co /ma/	-	-	-494.50K
Sio capital management	-	-	-320.39K

New Positions

Holder	Shares	% Assets	Change	Value
Susquehanna group, llp	72.80K	-	72.80K	$92.82K
Connor, clark & lunn investment management	46.09K	0.00%	46.09K	$133.66K
Prudential financial	25.84K	-	25.84K	$37.21K
Aqr capital management	12.49K	-	12.49K	$15.93K
Caldwell sutter capital	2.00K	0.00%	2.00K	$5.80K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-1.00
Capital performance advisors llp	-8.00
True wealth design	-13.00
Srs capital advisors	-15.00
Highmark wealth management	-50.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	26	-42.22%	4,054,360	-85.07%	5	0.42%	12	-20.00%	9	-52.63%
Sep 30, 2025	44	-2.22%	27,161,948	1.82%	35	2.90%	15	-11.76%	18	-14.29%
Jun 30, 2025	49	-14.04%	27,188,001	-4.17%	35	2.57%	19	-9.52%	23	-4.17%
Mar 31, 2025	57	-6.56%	30,474,260	-5.26%	40	2.23%	22	-35.29%	24	118.18%
Dec 31, 2024	22	-69.01%	4,265,950	-88.07%	5	0.25%	12	-67.57%	4	-78.95%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	720.43K	1.31%	-
Vanguard Total Stock Mkt Idx Inv	705.02K	1.25%	-15.41K
T. Rowe Price Health Sciences	653.96K	1.16%	-7.26K
Biotech Growth Ord	346.50K	0.61%	-
MFS New Discovery I	327.70K	0.60%	-
T. Rowe Price Small-Cap Value	168.61K	0.31%	-90.00
Fidelity Small Cap Index	144.77K	0.26%	-
Vanguard Institutional Extnd Mkt Idx Tr	142.55K	0.25%	-64.96K
MFS VIT New Discovery Init	104.99K	0.19%	-
State St Russell Sm/Mid Cp® Indx NL Cl C	104.70K	0.19%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 25, 2025	Combs Andrew	Chief Chemistry Officer	Buy	$69.25K
Mar 25, 2025	Vaddi Krishna	CEO	Buy	$467.44K
Mar 20, 2025	Vaddi Krishna	CEO	Buy	$3.95K
Mar 21, 2025	Vaddi Krishna	CEO	Buy	$10.96K
Mar 17, 2025	Vaddi Krishna	CEO	Buy	$6.83K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	8	-

PRLD Ownership FAQ

Who Owns Prelude Therapeutics?

Prelude Therapeutics shareholders are primarily institutional investors at 5.33%, followed by 9.93% insiders and 84.74% retail investors. The average institutional ownership in Prelude Therapeutics's industry, Biotech Stocks , is 384.56%, which Prelude Therapeutics falls below.

Who owns the most shares of Prelude Therapeutics?

Prelude Therapeutics’s largest shareholders are Orbimed advisors (10.91M shares, 14.36%), Baker bros. advisors lp (10.12M shares, 13.32%), and Boxer capital (2.57M shares, 3.39%). Together, they hold 31.07% of Prelude Therapeutics’s total shares outstanding.

Does Blackrock own Prelude Therapeutics?

Yes, BlackRock owns 1.41% of Prelude Therapeutics, totaling 1.07M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 4.07M$. In the last quarter, BlackRock decreased its holdings by -28.558K shares, a -2.60% change.

Who is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested?

Boxer capital is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.52% of its assets in 2.57M Prelude Therapeutics shares, valued at 9.79M$.

Who is the top mutual fund holder of Prelude Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Prelude Therapeutics shares, with 1.31% of its total shares outstanding invested in 720.43K Prelude Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools